6 terminated. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
| Phase 2 | 2 | Terminated 2 |
Follow Telangiectasis: new trials by email Literature Review of Telangiectasis trials Research Report on Telangiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension of EryDex Study IEDAT-04-2022 Dexamethasone sodium phosphate - Ataxia Telangiectasia | Phase 3 | Terminated | Quince Therapeutics S.p.A. | 101 | 2024-12-11 | 2026-05-05 |
| Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients Propranolol treatment, Placebo - Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease | Phase 3 | Terminated | University Hospital, Bordeaux | 15 | 2020-06-23 | 2026-06-23 |
| Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease Anti-VEGF injections of bevacizumab, Laser - Retinal Telangiectasis, Coats Disease | Phase 3 | Terminated | Fondation Ophtalmologique Adolphe de Rothschild | 18 | 2019-10-24 | 2025-12-10 |
| Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study EryDex System - Ataxia Telangiectasia, Genetic Syndrome | Phase 3 | Terminated | Quince Therapeutics S.p.A. | 104 | 2018-06-12 | 2024-10-08 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Bevacizumab, placebo - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Terminated | Hospices Civils de Lyon | 80 | 2014-04-01 | 2015-11-20 |
Ataxia Telangiectasia (2) · Epistaxis (2) · Telangiectasia, Hereditary Hemorrhagic (2) · CREST Syndrome (1) · Genetic Diseases, Inborn (1) · Peripheral Vascular Diseases (1) · Raynaud Disease (1) · Retinal Telangiectasis (1) · Scleroderma, Diffuse (1)
Cardiovascular Diseases (6) · Vascular Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Ataxia (2) · Brain Diseases (2) · Cardiovascular Abnormalities (2) · Central Nervous System Diseases (2) · Cerebellar Ataxia (2) · Cerebellar Diseases (2) · Congenital Abnormalities (2) · DNA Repair-Deficiency Disorders (2) · Dyskinesias (2)
Bevacizumab (1) · Lasers (1) · dexamethasone 21-phosphate (1)
Quince Therapeutics S.p.A. (2) · Fondation Ophtalmologique Adolphe de Rothschild (1) · Hospices Civils de Lyon (1) · Jose Soberon, MD (1) · University Hospital, Bordeaux (1)
France (3) · United States (3) · Germany (2) · Italy (2) · Norway (2) · Poland (2) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Denmark (1) · India (1) · Switzerland (1) · Tunisia (1)
Dirk Thye, MD (1) · Guenter R Janhofer, MD, PhD (1) · Jose Soberon, MD (1)
2016 (1), 2018 (1)